HIV/HBV Treatment Using CD8-Targeting Fusion Proteins
Summary
USPTO published patent application US20260098090A1 on April 9, 2026, disclosing fusion proteins for treating chronic viral infections including HIV and HBV. The application describes methods using CD8-targeting fusion proteins comprising antibodies specific to CD8b or CD8ab antigens combined with cytokines, chemokines, or growth factors. Inventors are Kelly Dare Moynihan, Yik Andy Yeung, and Ivana Djuretic, with filing date September 28, 2023.
What changed
USPTO published application US20260098090A1 on April 9, 2026, covering fusion proteins and methods for treating chronic viral infections such as HIV and HBV. The application claims fusion proteins combining CD8-targeting antibody moieties with cytokines, chemokines, or growth factors. The application was filed September 28, 2023, and is pending examination.
This publication establishes a priority date and discloses claimed subject matter that may eventually become granted patent rights. Pharmaceutical manufacturers, biotech companies, and researchers developing immunotherapies or antivirals for HIV or HBV should monitor this application's prosecution. Patent applications do not currently restrict others from developing similar products, but if granted, the patent could impose exclusivity on the claimed fusion protein compositions and treatment methods.
What to do next
- Monitor for updates on patent examination status
Archived snapshot
Apr 12, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
FUSIONS WITH CD8 ANTIGEN BINDING MOLECULES FOR TREATING CHRONIC VIRAL INFECTION
Application US20260098090A1 Kind: A1 Apr 09, 2026
Inventors
Kelly Dare MOYNIHAN, Yik Andy YEUNG, Ivana DJURETIC
Abstract
Provided herein are methods of treating chronic viral infection (e.g., hepatitis B virus (HBV) and/or human immunodeficiency virus (HIV) infection) comprising administering to an individual in need thereof an effective amount of a fusion protein that comprises: (a) a first moiety comprising an antibody or antigen-binding fragment thereof that specifically binds human CD8b and/or human CD8ab with at least 10-fold higher affinity than its binding to human CD8a and/or human CD8aa; and (b) a second moiety comprising a cytokine, chemokine, or growth factor.
CPC Classifications
C07K 16/2815 A61K 45/06 A61P 31/20 C07K 14/55 C07K 2317/24 C07K 2317/31 C07K 2317/522 C07K 2317/524 C07K 2317/526 C07K 2317/53 C07K 2317/565 C07K 2317/569 C07K 2317/622 C07K 2317/92 C07K 2319/30
Filing Date
2023-09-28
Application No.
19114281
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.